Tylomaibo announced that the company's self-developed, Class 1 innovative drug for children, was approved for marketing by the State Drug Administration through a priority review and approval procedure. The approved indications are to prevent lower respiratory infections caused by RSV in newborns and infants about to enter or be born during the first respiratory syncytial virus epidemic season. This product is the world's first single-dose RSV monoclonal antibody with nine months of clinical protection data. This approval marks the launch of the company's second self-developed innovative all-human monoclonal antibody drug. It will not have a significant impact on the company's current financial situation and operating results, and will have a positive effect on future performance improvement.

Tylomaibo announced that the company's self-developed, Class 1 innovative drug for children, was approved for marketing by the State Drug Administration through a priority review and approval procedure. The approved indications are to prevent lower respiratory infections caused by RSV in newborns and infants about to enter or be born during the first respiratory syncytial virus epidemic season. This product is the world's first single-dose RSV monoclonal antibody with nine months of clinical protection data. This approval marks the launch of the company's second self-developed innovative all-human monoclonal antibody drug. It will not have a significant impact on the company's current financial situation and operating results, and will have a positive effect on future performance improvement.